$89.6 B

BMY Mkt cap, 15-Jun-2018

$5.2 B

Bristol-Myers Squibb Revenue Q1, 2018
Bristol-Myers Squibb Gross profit (Q1, 2018)3.6 B
Bristol-Myers Squibb Gross profit margin (Q1, 2018), %69.5%
Bristol-Myers Squibb Net income (Q1, 2018)1.5 B
Bristol-Myers Squibb Cash, 31-Mar-20185.3 B
Bristol-Myers Squibb EV90 B

Bristol-Myers Squibb Financials

Bristol-Myers Squibb Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

16.4 b15.9 b16.6 b19.4 b

Revenue growth, %

(3%)4%17%

Cost of goods sold

4.6 b3.9 b3.9 b4.9 b

Gross profit

11.8 b11.9 b12.7 b14.5 b

Gross profit Margin, %

72%75%76%75%

Pre tax profit

2.9 b2.4 b2.1 b5.9 b

Income tax expense

311 m352 m446 m1.4 b

Net Income

2.6 b2 b1.6 b4.5 b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

4.1 b3.8 b3.9 b3.9 b4 b4.2 b4.1 b4.4 b4.9 b4.9 b4.9 b5.1 b5.3 b5.2 b

Cost of goods sold

1.2 b968 m991 m1 b847 m1 b1.1 b1.1 b1.2 b1.3 b1.3 b1.6 b1.6 b1.6 b

Gross profit

2.9 b2.8 b2.9 b2.9 b3.2 b3.2 b3 b3.3 b3.7 b3.6 b3.7 b3.6 b3.7 b3.6 b

Gross profit Margin, %

71%75%75%74%79%76%73%76%75%73%74%70%70%69%

R&D expense

893 m946 m1.4 b983 m1 b1.9 b1.1 b1.1 b1.3 b1.1 b1.3 b1.7 b1.5 b1.3 b

Operating expense total

3.2 b2.8 b3.4 b2.9 b2.6 b4.1 b3.1 b2.7 b3.3 b3.4 b3 b3.8 b4.1 b3.4 b

Pre tax profit

985 m448 m1 b1.4 b52 m987 m1.7 b1.6 b1.6 b2 b1.3 b1.2 b1.8 b

Income tax expense

49 m114 m276 m249 m162 m257 m449 m427 m344 m429 m373 m327 m284 m

Net Income

936 m334 m732 m1.2 b730 m1.2 b1.2 b1.5 b922 m856 m1.5 b

Bristol-Myers Squibb Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.6 b5.6 b2.4 b4.2 b

Inventories

1.5 b1.6 b1.2 b1.2 b

Current Assets

18.9 b14.6 b10.4 b13.7 b

Goodwill

7.1 b7 b6.9 b6.9 b

Total Assets

38.6 b33.7 b31.7 b33.7 b

Accounts Payable

2.6 b2.5 b1.6 b1.7 b

Dividends Payable

634 m645 m655 m

Short-term debt

359 m590 m139 m992 m

Current Liabilities

12.4 b8.5 b8 b8.8 b

Long-term debt

8 b7.2 b6.6 b5.7 b

Total Debt

8.3 b7.8 b6.7 b6.7 b

Retained Earnings

33 b32.5 b31.6 b33.5 b

Total Equity

15.2 b15 b14.4 b16.3 b

Debt to Equity Ratio

0.5 x0.5 x0.5 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.2 x

Financial Leverage

2.5 x2.3 x2.2 x2.1 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

4.2 b4 b2.6 b2.9 b3.4 b3.9 b3.5 b4.6 b5.3 b

Accounts Receivable

5.7 b

Inventories

1.3 b1.1 b1.3 b1.4 b1.5 b1.4 b1.2 b1.3 b1.2 b

Current Assets

13.1 b12.9 b11.2 b12.3 b13.2 b13.6 b14.3 b15 b14.6 b

Goodwill

7 b7 b6.9 b6.9 b6.9 b6.9 b6.9 b6.9 b6.9 b

Total Assets

32 b31.8 b31.9 b32.8 b33.7 b32.9 b33.4 b34 b33.1 b

Accounts Payable

1.8 b1.2 b1.5 b1.5 b1.4 b1.5 b1.6 b1.7 b1.7 b

Dividends Payable

634 m636 m

Short-term debt

755 m642 m106 m155 m990 m

Current Liabilities

7.4 b7.2 b7.6 b7.9 b9 b8.5 b9 b9.4 b9.6 b

Long-term debt

6.6 b6.6 b6.6 b6.6 b5.8 b7.2 b6.9 b7 b5.8 b

Total Debt

7.4 b7.3 b6.7 b6.7 b6.8 b7.2 b6.9 b7 b5.8 b

Total Liabilities

16.7 b16.5 b17.3 b17.8 b17.9 b18.4 b18.6 b19.1 b20.2 b

Common Stock

221 m221 m221 m221 m

Retained Earnings

32.4 b32.4 b32.2 b32.7 b33.3 b33.7 b33.9 b34.1 b32.3 b

Total Equity

15.3 b15.3 b14.6 b15.1 b15.8 b14.5 b14.8 b14.9 b12.9 b

Financial Leverage

2.1 x2.1 x2.2 x2.2 x2.1 x2.3 x2.3 x2.3 x2.6 x

Bristol-Myers Squibb Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

2.6 b2 b1.6 b4.5 b

Inventories

(45 m)(254 m)97 m(152 m)

Accounts Payable

412 m(44 m)(919 m)104 m

Cash From Operating Activities

3.5 b3.1 b1.8 b2.9 b

Cash From Investing Activities

(572 m)1.2 b(1.6 b)1.5 b

Long-term Borrowings

(597 m)(676 m)(2 b)(15 m)

Cash From Financing Activities

(1.1 b)(2.4 b)(3.4 b)(2.4 b)

Free Cash Flow

2.7 b4.1 b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

1.8 b936 m1.3 b2 b1.2 b1.1 b1.8 b1.2 b2.4 b3.6 b1.5 b2.4 b3.3 b1.5 b

Accounts Receivable

219 m

Inventories

(8 m)(144 m)(157 m)(162 m)51 m162 m231 m(44 m)(111 m)(107 m)(71 m)(58 m)7 m(4 m)

Accounts Payable

301 m(12 m)(112 m)63 m(83 m)(618 m)(1.2 b)(77 m)(36 m)(142 m)(114 m)(85 m)63 m(241 m)

Cash From Operating Activities

2.1 b1.7 b2.6 b626 m697 m1.2 b25 m1.4 b2.4 b4.2 b1.2 b

Cash From Investing Activities

(257 m)2.2 b701 m865 m754 m(526 m)(588 m)1.4 b1.8 b1.5 b(203 m)(1.2 b)(1.1 b)(43 m)

Long-term Borrowings

(676 m)(676 m)(676 m)(676 m)(2 b)(2 b)(2 b)(2 b)(474 m)(1.2 b)

Cash From Financing Activities

(1.8 b)(1.2 b)(1.7 b)(2.2 b)(682 m)(1.6 b)(2.3 b)(792 m)(1.3 b)(1.9 b)(1 b)(2 b)(2.7 b)(1.2 b)

Free Cash Flow

(478 m)578 m1.9 b3.4 b936 m

Bristol-Myers Squibb Ratios

USDY, 2018

EV/CFO

76.6 x

EV/FCF

96.2 x

Financial Leverage

2.6 x
Report incorrect company information

Bristol-Myers Squibb Operating Metrics

Y, 2015Y, 2016

Phase III Trials Products

2 8

Projects in R&D Pipeline

32 44
Report incorrect company information